|
|
|
| The clinical efficacy of Tongyang Quyu Decoction with combination chemotherapy scheme in the treatment of Her-2 positive breast cancer |
| HE Na′na WANG Qiaolin CHEN Yin |
| The First Department of Oncology, Traditional Chinese Medicine Hospital, Xinjiang Uygur Autonomous Region, Urumqi 830000, China |
|
|
|
Abstract Objective To investigate the clinical efficacy of Tongyang Quyu Decoction with combination chemotherapy scheme in the treatment of human epidermal growth factor receptor 2 (Her-2) positive breast cancer. Methods 150 cases with Her-2 positive breast cancer received in Traditional Chinese Medicine Hospital from May 2013 to May 2016 were divided into control group (75 cases) and observation group (75 cases) by random number table. The control group was treated with trastuzumab based chemotherapy, while the observation group was treated with Tongyang Quyu Decoction assisted with combination chemotherapy scheme. The two groups were treated for 18 weeks. The TCM Syndrome scores of breast cancer patients, quality of life scale (FACT-B) score, blood rheology, serum level of cardiac troponin (cTnI), heart fatty acid binding protein (H-FABP), interleukin -6 (IL-6) and tumor necrosis factor -a (TNF- alpha) and poison side effect difference in patients were compareds. Results The objective response rate and clinical benefit rate in the observation group were significantly higher than those in the control group (P < 0.05). The TCM Syndrome scores in the observation group after treatment were significantly lower than those in the control group (P < 0.05). The physiological status, family status, emotional status, social function, additional attention index FACT-B score in the observation group were lower than those in the control group (P < 0.05). Whole blood viscosity, whole blood viscosity, whole blood low shear viscosity, plasma viscosity, cTnI, H-FABP, IL-6 and TNF- levels of the observation group after treatment were significantly lower than those of the control group (P < 0.05). The incidence rate of observation group was lower than that of the control group (P < 0.05). Conclusion The treatment of Her-2 positive breast cancer with Tongyang Quyu Decoction with combination chemotherapy scheme can effectively control the progress of disease, have better clinical treatment effect and improve the quality of life of patients.
|
|
|
|
|
|
[1] Sinn P，Aulmann S，Wirtz R，et al. Multigene assays for classification，prognosis，and prediction in breast cancer：a critical review on the background and clinical utility [J]. Geburtshilfe Frauenheilkd， 2013，73（9）：932-940.
[2] 林潇，胡倩，姚和瑞，等.转移性乳腺癌的化疗策略[J].中华临床医师杂志：电子版，2015，9（6）：966-971.
[3] Slamon D，Eiermann W，Robert N，et al. Adjuvant trastuzumab in HER2-positive breast cancer [J]. N Engl J Med，2011， 365（14）：1273-1283.
[4] 刘伟，段昕波，徐鑫.心脉隆注射液对蒽环类药物所致心脏毒性的预防效果研究[J].中国全科医学，2014，17（29）：3461-3464.
[5] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范（2013版）[J].中国癌症杂志，2013，23（8）：637-684.
[6] 郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社，2002.
[7] 国家中医药管理局.中医病证诊断疗效标准[M].南京：南京大学出版社，2012.
[8] 万崇华，张冬梅，汤学良，等.乳腺癌患者生命质量测定量表（FACT-B）中文版的修订[J].中国心理卫生杂志，2003，17（5）：298-300.
[9] Jackisch C，Welslau M，Schoenegg W，et al. Impact of trastuzumab treatment beyond disease progression for advanced/metastatic breast cancer on survival results from a prospective，observational study in Germany [J]. Breast，2014，23（5）：603-608.
[10] 胡赛男，张莉莉.跨线曲妥珠单抗联合不同化疗方案治疗HER2阳性晚期乳腺癌的临床研究[J].肿瘤防治研究，2016，43（1）：39-44.
[11] Andersson M，Lidbrink E，Bjerre K，et al. Phase Ⅲ randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer：the HERNATA study [J]. J Clin Oncol，2011，29（3）：264-271.
[12] 薛金贵，王肖龙，许勇，等.心脉隆注射液治疗慢性心力衰竭（气阳两虚、瘀血内阻证）的多中心随机对照研究[J].中国中西医结合杂志，2015，35（7）：796-800.
[13] 孙飞，张楚，虞萍，等.中医药在乳腺癌综合疗法中的地位评价[J].中华中医药杂志，2010，25 （8）：1275-1280.
[14] 陈国辉，黄文凤.黄芪的化学成分及药理作用研究进展[J].中国新药杂志，2008，17（17）：1482-1485.
[15] 何道同，王兵，陈珺明.人参皂苷药理作用研究进展[J].辽宁中医药大学学报，2012，14（7）：118-121.
[16] 苗耀东，李小江，贾英杰，等.猫爪草的化学成分及药理作用研究进展[J].中草药，2014，45（11）： 1651-1654.
[17] 曾志强，姜镭，黄婉文，等.磷酸肌酸对乳腺癌术后化疗患者心肌损伤标志物的影响[J].重庆医学，2013，42（27）：3291-3292.
[18] 刘宇红，高东美，张友良，等.心型游离脂肪酸结合蛋白定性检查在急性非ST段抬高型心肌梗死超早期鉴别诊断中的应用[J].中华临床医师杂志，2012，6（5）：1298-1299.
[19] Adelibieke Y，Yisireyili M，Ng HY，et al. Indoxyl sulfate induces IL-6 expression in vascular endothelial and smooth muscle cells through OAT3-mediated uptake and activation of AhR/NF-κB pathway [J]. Nephron Exp Nephrol，2014（1-2）：1-8.
[20] 牟微娜，李苗，谢长生. 78例三阴性乳腺癌的临床特征和中医证型分析[J].肿瘤学杂志，2014，20（2）：106-109.
[21] 金明子，王丽祯，沈雪勇.中医外治法治疗乳腺癌相关上肢淋巴水肿的研究进展[J].中国中医急症，2017，26（3）：464-468. |
|
|
|
